Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer

2014-08-27 03:43:37 | BioPortfolio


The purpose of this study is to determine the acute and late toxicities from radiation therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks for 12 weeks), bicalutamide (every day for 16 weeks) and goserelin (every 3 months for 2 years).


Although there is no data on the toxicity with concurrent bevacizumab and hormonal therapy, the combination is not expected to increase toxicity seen when given as a single agent. Abnormal tumor microenvironments, tumor progression, and metastatic spread are major factors contributing to treatment failures in radiotherapy. Anti-VEGF agents (e.g. bevacizumab) can help overcome these factors through several different mechanisims.

Studies also demonstrate prolonged use of anti-VEGF agents with radiation therapy was more effective at preventing metastases from irradiated tumors compared to a short course. Patients generally start hormonal therapy and daily radiotherapy at the same time. This study will delay the start of radiotherapy until 8 weeks after the start of hormonal therapy and bevacizumab.

Study Design

Allocation: Non-Randomized, Control: Historical Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Prostate Cancer


bevacizumab, bicalutamide and goserelin, intensity modulated radiation therapy (IMRT)


Virginia Mason Medical Center
United States




Benaroya Research Institute

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:43:37-0400

Clinical Trials [3651 Associated Clinical Trials listed on BioPortfolio]

Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Androgen Deprivation Therapy for Metastatic Prostate Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cel...

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone. It is not yet k...

Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial

The goal of this clinical research study is to learn how safe and effective proton-beam therapy (PBT) may be in comparison to intensity modulated radiation therapy (IMRT) in combination wi...

Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy

The goal of this clinical research study is to use CT scans to find any changes in position of the vagina and pelvic lymph node areas during the course of intensity modulated radiotherapy ...

Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer

This study is being performed to understand the safety of a new radiation treatment called "Multi-Beam Intensity Modulated Radiation Therapy" ( IMRT). Currently, the standard way of giving...

PubMed Articles [14176 Associated PubMed Articles listed on BioPortfolio]

Utilization of Neoadjuvant Intensity-modulated Radiation Therapy for Rectal Cancer in the United States.

Advances in technology have expanded the use of intensity-modulated radiotherapy (IMRT). The goal of this study was to investigate trends in the utilization of IMRT for rectal cancer (RC) in USA.

Flattening filter free in intensity modulated radiotherapy (IMRT) - theoretical modeling with delivery efficiency analysis.

The flattening filter (FF) has traditionally been used to flatten beams or create uniform fields in conformal and intensity-modulated radiation therapy (IMRT) but reduces the dose rate. Many studies h...

Intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation therapy (3D-CRT) for head and neck cancer: cost-effectiveness analysis.

A cost-effectiveness analysis of IMRT compared to 3D-CRT for head and neck cancer patients (HNCPs) was conducted in the Brazilian Public Health System.

Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma.

Technological advancements in treatment planning and delivery have propelled the use of intensity-modulated radiation therapy (IMRT) in head and neck squamous cell carcinoma (HNSCC). This review compa...

Patterns of Local-Regional Failure after Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy with Concurrent Chemotherapy for Non-Small Cell Lung Cancer.

We compared differences in patterns of local-regional failure, and the influence of adaptive planning on those patterns, in patients given passive scattering proton therapy (PSPT) vs. intensity-modula...

Medical and Biotech [MESH] Definitions

CONFORMAL RADIOTHERAPY that combines several intensity-modulated beams to provide improved dose homogeneity and highly conformal dose distributions.

A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

Organs which might be damaged during exposure to a toxin or to some form of therapy. It most frequently refers to healthy organs located in the radiation field during radiation therapy.

Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other, e.g. military, purposes.

More From BioPortfolio on "Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer"

Quick Search


Searches Linking to this Trial